Candriam SCA’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $37.5M | Sell |
|
|||||
|
2025
Q1 | $36.6M | Buy |
|
|||||
|
2024
Q4 | $41.5M | Sell |
|
|||||
|
2024
Q3 | $55.7M | Buy |
|
|||||
|
2024
Q2 | $64.1M | Buy |
|
|||||
|
2024
Q1 | $43.5M | Sell |
|
|||||
|
2023
Q4 | $48.7M | Sell |
|
|||||
|
2023
Q3 | $42.4M | Sell |
|
|||||
|
2023
Q2 | $41.5M | Buy |
|
|||||
|
2023
Q1 | $38.9M | Buy |
|
|||||
|
2022
Q4 | $32.1M | Sell |
|
|||||
|
2022
Q3 | $28.8M | Sell |
|
|||||
|
2022
Q2 | $32.3M | Buy |
|
|||||
|
2022
Q1 | $28.1M | Sell |
|
|||||
|
2021
Q4 | $26.4M | Buy |
|
|||||
|
2021
Q3 | $7.82M | Buy |
|
|||||
|
2021
Q2 | $7.93M | Sell |
|
|||||
|
2021
Q1 | $15.9M | Hold |
|
|||||
|
2020
Q4 | $16.6M | Buy |
|
|||||
|
2020
Q3 | $15M | Hold |
|
|||||
|
2020
Q2 | $19.1M | Sell |
|
|||||
|
2020
Q1 | $19.6M | Hold |
|
|||||
|
2019
Q4 | $20.1M | Sell |
|
|||||
|
2019
Q3 | $18.4M | Sell |
|
|||||
|
2019
Q2 | $22.5M | Sell |
|
|||||
|
2019
Q1 | $25.8M | Buy |
|
|||||
|
2018
Q4 | $16.3M | Buy |
|
|||||
|
2018
Q3 | $18.5M | Buy |
|
|||||
|
2018
Q2 | $7.87M | Buy |
|
|||||
|
2018
Q1 | $5.39M | Sell |
|
|||||
|
2017
Q4 | $7.76M | Sell |
|
|||||
|
2017
Q3 | $24M | Sell |
|
|||||
|
2017
Q2 | $21.2M | Buy |
|
|||||
|
2017
Q1 | $10.7M | Buy |
|
|||||
|
2016
Q4 | $6.54M | Buy |
|
|||||
|
2016
Q3 | $6.23M | Buy |
|
|||||
|
2016
Q2 | $5.29M | Sell |
|
|||||
|
2016
Q1 | $4.68M | Buy |
|
|||||
|
2015
Q4 | $6.34M | Buy |
|
|||||
|
2015
Q3 | $3.62M | Sell |
|
|||||
|
2015
Q2 | $5.01M | Sell |
|
|||||
|
2015
Q1 | $6.16M | Sell |
|
|||||
|
2014
Q4 | $4.69M | Buy |
|